Clinical Trial Update: Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children [Phase 2]

View source ↗

Summary

The document discusses a Phase 2 trial of low-dose selumetinib for plexiform neurofibromas in Chinese children. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Sponsor: West China Hospital | Conditions: Plexiform Neurofibromas (PN) | Phase 2 | Status: NOT_YET_RECRUITING